276 related articles for article (PubMed ID: 16507364)
1. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis.
Nominé Y; Masson M; Charbonnier S; Zanier K; Ristriani T; Deryckère F; Sibler AP; Desplancq D; Atkinson RA; Weiss E; Orfanoudakis G; Kieffer B; Travé G
Mol Cell; 2006 Mar; 21(5):665-78. PubMed ID: 16507364
[TBL] [Abstract][Full Text] [Related]
2. Specific recognition of four-way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6.
Ristriani T; Nominé Y; Masson M; Weiss E; Travé G
J Mol Biol; 2001 Jan; 305(4):729-39. PubMed ID: 11162088
[TBL] [Abstract][Full Text] [Related]
3. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
4. HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognizes four-way junctions.
Ristriani T; Masson M; Nominé Y; Laurent C; Lefevre JF; Weiss E; Travé G
J Mol Biol; 2000 Mar; 296(5):1189-203. PubMed ID: 10698626
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
[TBL] [Abstract][Full Text] [Related]
6. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.
Giovane C; Trave G; Briones A; Lutz Y; Wasylyk B; Weiss E
J Mol Recognit; 1999; 12(2):141-52. PubMed ID: 10398405
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells.
Pim D; Storey A; Thomas M; Massimi P; Banks L
Oncogene; 1994 Jul; 9(7):1869-76. PubMed ID: 8208532
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of HPV E6 proteins in cellular transformation.
Huibregtse JM; Beaudenon SL
Semin Cancer Biol; 1996 Dec; 7(6):317-26. PubMed ID: 9284524
[TBL] [Abstract][Full Text] [Related]
9. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur CP; Marcus B; Dalal S; Androphy EJ
Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
[TBL] [Abstract][Full Text] [Related]
10. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
Pim D; Banks L
Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP.
Sherman L; Itzhaki H; Jackman A; Chen JJ; Koval D; Schlegel R
Virology; 2002 Jan; 292(2):309-20. PubMed ID: 11878933
[TBL] [Abstract][Full Text] [Related]
12. E6*, the 50 amino acid product of the most abundant spliced transcript of the e6 oncoprotein in high-risk human papillomavirus, is a promiscuous folder and binder.
Heer A; Alonso LG; de Prat-Gay G
Biochemistry; 2011 Mar; 50(8):1376-83. PubMed ID: 21226480
[TBL] [Abstract][Full Text] [Related]
13. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
[TBL] [Abstract][Full Text] [Related]
14. Domain substructure of HPV E6 oncoprotein: biophysical characterization of the E6 C-terminal DNA-binding domain.
Nominé Y; Charbonnier S; Ristriani T; Stier G; Masson M; Cavusoglu N; Van Dorsselaer A; Weiss E; Kieffer B; Travé G
Biochemistry; 2003 May; 42(17):4909-17. PubMed ID: 12718532
[TBL] [Abstract][Full Text] [Related]
15. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
16. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs.
Uversky VN; Roman A; Oldfield CJ; Dunker AK
J Proteome Res; 2006 Aug; 5(8):1829-42. PubMed ID: 16889404
[TBL] [Abstract][Full Text] [Related]
17. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines.
Liang XH; Volkmann M; Klein R; Herman B; Lockett SJ
Oncogene; 1993 Oct; 8(10):2645-52. PubMed ID: 8397367
[TBL] [Abstract][Full Text] [Related]
18. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
19. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6.
Gu Z; Pim D; Labrecque S; Banks L; Matlashewski G
Oncogene; 1994 Feb; 9(2):629-33. PubMed ID: 8290274
[TBL] [Abstract][Full Text] [Related]
20. HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence.
Thomas M; Massimi P; Banks L
Oncogene; 1996 Aug; 13(3):471-80. PubMed ID: 8760288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
